Rep. Lisa C. McClain Purchases Shares of Pfizer Inc. (NYSE:PFE)

Representative Lisa C. McClain (R-Michigan) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on July 16th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Autoliv (NYSE:ALV) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of XPO (NYSE:XPO) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Lithia Motors (NYSE:LAD) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Sanofi (NASDAQ:SNY) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Group 1 Automotive (NYSE:GPI) on 7/22/2025.

Pfizer Trading Up 0.2%

Shares of NYSE PFE opened at $25.16 on Monday. The firm’s 50 day moving average price is $24.60 and its 200-day moving average price is $24.42. The company has a market cap of $143.05 billion, a PE ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PFE shares. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. The Goldman Sachs Group upped their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Leerink Partners dropped their target price on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 30th. Finally, TD Cowen dropped their target price on shares of Pfizer from $32.00 to $28.00 and set a “hold” rating on the stock in a research note on Tuesday, April 22nd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.12.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC increased its holdings in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 388 shares during the last quarter. Citizens National Bank Trust Department increased its holdings in Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 395 shares during the last quarter. Peak Asset Management LLC increased its holdings in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after buying an additional 402 shares during the last quarter. Able Wealth Management LLC increased its holdings in Pfizer by 2.0% during the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after buying an additional 413 shares during the last quarter. Finally, Trust Co of the South increased its holdings in Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 441 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.